In 2023, Sarepta Therapeutics conducted an environmental assessment and disclosed corporate waste management data in accordance with recognized sustainability reporting standards. The company provided a breakdown of its waste by type (hazardous vs non-hazardous) and treatment method (recovery vs disposal), enabling greater transparency into its waste handling and environmental practices.
Metric (tonnes) | 2024 | 2023 | 2022 | 2021 - 2017 |
---|---|---|---|---|
Total Waste Generated | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Waste Recovered | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Hazardous Waste Generated | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Non-Hazardous Waste Disposed | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
This table provides a simplified preview of selected waste data points. To access the complete dataset with full disclosures and structure, create a free account to purchase the full dataset.
In 2023, Sarepta Therapeutics generated a total of 214 metric tonnes of waste.
Of this amount, 11.21% of Sarepta Therapeutics's total waste generated of was classified as hazardous waste, characterized by properties such as toxicity, flammability, corrosiveness, or reactivity that may pose risks to human health, ecosystems, or the environment. 88.79% was identified as non-hazardous waste, generally considered less harmful and subject to lighter regulatory controls.
Since 2023, Sarepta Therapeutics's total waste generation has increased by 43.62%, which may reflect expanding operations, weaker material efficiency, or insufficient waste reduction efforts.
Since 2023, Sarepta Therapeutics's hazardous waste generation has increased by 19.36%, indicating a potential rise in the use of harmful materials, process inefficiencies, or limited hazardous waste reduction strategies..
Overall, Sarepta Therapeutics has seen a recent increase in both total waste and hazardous waste, which may indicate growing operational pressures or insufficient controls on harmful materials.